Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens

Abstract

Relaxin is negatively regulated by androgens in vitro and in vivo, which correlates to clinical prostate cancer specimens following androgen ablation. The role of relaxin in angiogenesis and tissue remodeling suggests it may contribute to prostate cancer progression.